郭新贵

• 1:上海华东医院心内科

摘要(Abstract)：

<正>动脉粥样硬化继以血小板激活、聚集导致血栓形成是冠心病急性缺血事件的主要发生机制,因此,抗血小板药物治疗是防治冠心病的重要手段。阿司匹林仍是目前治疗的基石,其与氯吡格雷的联合应用是经皮冠状动脉介入治疗(PCI)术后双联抗血小板治疗的标准方案,但广泛应用易增加出血风险、药物抵抗及外科术前桥接等问题仍困扰临床。以普拉格雷和替格瑞洛为代表的新型P2Y12抑制剂应运而

关键词(KeyWords)： 指南解读;新型P2Y12抑制剂

Abstract:

Keywords:

基金项目(Foundation):

作者(Author): 郭新贵

参考文献(References)：

• [1]Steg PG,James SK,Atar D,et al.ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation:The Task Force on the management of ST-segment elevation acute myocardial infarction of the European Society of Cardiology(ESC).Eur Heart J,2012,33:2569-2619.
• [2]American College of Emergency Physicians,Society for Cardiovascular Angiography and Interventions,O'Gara PT,et al.2013 ACCF/AHA guideline for the management of ST-elevation myocardial infarction:a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines.J Am Coll Cardiol,2013,61:e78-140.
• [3]Hamm CW,Bassand JP,Agewall S,et al.ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation:The Task Force for the management of acute coronary syndromes(ACS)in patients presenting without persistent ST segment elevation of the European Society of Cardiology(ESC).Eur Heart J,2011,32:2999-3054.
• [4]2012 Writing Committee Members,Jneid H,Anderson JL,et al.2012 ACCF/AHA Focused Update of the Guideline for the Management of Patients With Unstable Angina/Non-ST-Elevation Myocardial Infarction(Updating the 2007 Guideline and Replacing the 2011 Focused Update):A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines.Circulation,2012,126:875-910.
• [5]Task Force Members,Montaluscot G,Sechtem U,et al.2013ESC guidelines on the management of stable coronary artery disease-The task force on the management of stable coronary artery disease of the European Society of Cardiology.Eur Heart J,2013,34:2949-3003.
• [6]Yusuf S,Zhao F,Mehta SR,et al.Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.N Eng J Med,2001,345:494-502.
• [7]Montalescot G,Wiviott SD,Braunwald E,et al.Prasugrel compared with clopidogrel in patients undergoing percutaneous coronary intervention for ST-elevation myocardial infarction(TRITON-TIMI38):double-blind,randomised controlled trial.Lancet,2009,373:723-731.
• [8]Steg PG,James S,Harrington RA,et al.Ticagrelor versus clopidogrel in patients with ST-elevation acute coronary syndromes intended for reperfusion with primary percutaneous coronary intervention:A Platelet Inhibition and Patient Outcomes(PLATO)trial subgroup analysis.Circulation,2010,122:2131-2141.
• [9]Mehta SR,Yusuf S,Peters RJ,et al.Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention:the PCI-CURE study.Lancet,2001,358:527-533.
• [10]Chen ZM,Jiang LX,Chen YP,et al.Addition of clopidogrel to aspirin in 45,852 patients with acute myocardial infarction:randomized placebo-controlled trial.Lancet,2005,366:1607-1621.
• [11]Capodanno D,Ferreiro JL,Angiolillo DJ.Antiplatelet therapy:new pharmacological agents and changing paradigms.J Thromb Haemost,2013,11:316-329.
• [12]Mehta SR,Tanguay JF,Eikelboom JW,et al.Double-dose versus standard-dose clopidogrel and high-dose versus low-dose aspirin in individuals undergoing percutaneous coronary intervention for acute coronary syndromes(CURRENT-OASIS 7):a randomised factorial trial.Lancet,2010,376:1233-1243.